Albeit not statistically significant for OS, the primary endpoint, these results suggest a clinical benefit of nivolumab for advanced HCC, with meaningful improvements in response rate and survival, especially for the patients who have PD-L1 expression ≥1%. This evidence concerns the gene CD274 and hepatocellular carcinoma.